Jane Street
PMCB icon

Jane Street’s PharmaCyte Biotech PMCB Stock Holding History

Jane Street’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Buy
30,064
+18,534
+161% +$14K ﹤0.01% 11165
2026
Q1 		$7.67K Buy
11,530
+139
+1% +$106 ﹤0.01% 11327
2025
Q4 		$8.25K Buy
+11,391
New +$10.3K ﹤0.01% 10867
2023
Q1 		– Sell
-20,705
Closed -$60.7K – 9721
2022
Q4 		$60.7K Buy
+20,705
New +$59.3K ﹤0.01% 8300

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Jane Street's PMCB Position: Q2 2026 in Review

Jane Street increased its PharmaCyte Biotech (PMCB) stake by 161% in Q2 2026, buying an estimated $14K and bringing the position to 30,064 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #11165.

Jane Street first reported a position in PMCB in Q4 2022 and has held it in 4 quarters since. The position peaked at $60.7K in Q4 2022. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Jane Street held 30,064 shares of PharmaCyte Biotech worth $23.1K as of Q2 2026.
  • Jane Street bought 18,534 PharmaCyte Biotech shares in Q2 2026, an estimated $14K.
  • PharmaCyte Biotech made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11165 holding.
  • Jane Street first reported a position in PharmaCyte Biotech in Q4 2022 and has held it in 4 quarters since.
  • Jane Street's PharmaCyte Biotech position peaked at $60.7K in Q4 2022.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.